<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">Solid tumors</z:e> are dependent on preexisting vasculature and neovascularization for their growth </plain></SENT>
<SENT sid="1" pm="."><plain>Successful <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies targeting the <z:e sem="disease" ids="C1658953" disease_type="Neoplastic Process" abbrv="">tumor vasculature</z:e> would be expected to block the existing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> blood supply and to prevent <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> neovascularization </plain></SENT>
<SENT sid="2" pm="."><plain>We tested the antitumor activity of experimental therapy with 2 distinct antiangiogenic drugs </plain></SENT>
<SENT sid="3" pm="."><plain>Vasostatin inhibits endothelial cell growth and neovascularization, and interleukin-12 (IL-12) targets the <z:e sem="disease" ids="C1658953" disease_type="Neoplastic Process" abbrv="">tumor vasculature</z:e> acting through interferon-gamma (IFN-gamma) and the downstream chemokines interferon-inducible protein-10 (IP-10) and monokine induced by IFN-gamma </plain></SENT>
<SENT sid="4" pm="."><plain>Individually, vasostatin and IL-12 produced distinct efficacy profiles in trials aimed at reducing <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in athymic mice </plain></SENT>
<SENT sid="5" pm="."><plain>In combination, these inhibitors halted the growth of human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, colon <z:mp ids='MP_0002038'>carcinoma</z:mp>, and <z:mp ids='MP_0003579'>ovarian carcinoma</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapy that combines distinct inhibitors of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> is a novel, effective strategy for the experimental treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>(Blood </plain></SENT>
<SENT sid="8" pm="."><plain>2000;96:1900-1905) </plain></SENT>
</text></document>